Otsuka : Complete Introduction of CO2-free Electricity for All 23 Manufacturing Facilities in Japan -Contributing to a more than 40% reduction in annual CO2 emissions in Japan
June 09, 2021 at 09:18 am EDT
Share
Otsuka Holdings Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President and Representative Director, CEO: Tatsuo Higuchi) has completed introduction of CO2-free electricity at all manufacturing facilities of five subsidiary companies in Japan. Derived from renewable energy sources that do not produce CO2 emissions, CO2-free electricity*1 has been introduced at domestic manufacturing facilities of Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Taiho Pharmaceutical Co., Ltd., Otsuka Chemical Co., Ltd., and Otsuka Foods Co., Ltd.
The Otsuka group of companies has identified climate change, resource recycling and conservation, and water conservation as important areas (material issues) for environmental initiatives. Regarding climate change, the goal of a 30% global reduction by 2030*2 is the focus of proactive efforts to reduce CO2 emissions. Adoption of CO2-free electricity at manufacturing facilities, which tend to produce a higher volume of CO2 emissions, began in July 2019. The recent adoption of CO2-free electricity at the Taiho Pharmaceutical Inuyama manufacturing facility in Aichi Prefecture completes the introduction of CO2-free electricity at all 23 manufacturing facilities of five Otsuka subsidiary companies in Japan. In addition to CO2-free electricity, proactive efforts to reduce CO2 emissions include optimization of energy use through adoption of self-consuming solar power generation, cogeneration, and other fuel conversion systems*3. These combined efforts are predicted to result in a 41% reduction*4 in CO2 emissions during FY2021. Hereafter, proactive implementation of overseas initiatives is planned to ensure achievement of our global goals. The Otsuka group aims to rely on synergy generated by collaboration among group companies to contribute to a low-carbon, more sustainable society.
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
Otsuka : Complete Introduction of CO2-free Electricity for All 23 Manufacturing Facilities in Japan -Contributing to a more than 40% reduction in annual CO2 emissions in Japan
OTSUKA HOLDINGS CO., LTD. 
